Abstract 1753: GLPG1790: The first Ephrin (EPH) receptor tyrosine kinase inhibitor for the treatment of triple negative breast cancer

Mapping Intimacies ◽

10.1158/1538-7445.am2014-1753 ◽

2014 ◽

Author(s):

Philippe Pujuguet ◽

Filip Beirinckx ◽

Carole Delachaume ◽

Jacques Huck ◽

Ellen Van der Aar ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Triple Negative Breast Cancer ◽

Receptor Tyrosine Kinase ◽

Triple Negative ◽

Kinase Inhibitor ◽

Eph Receptor ◽

Receptor Tyrosine Kinase Inhibitor

Download Full-text

Therapeutic activity of DCC‐2036, a novel tyrosine kinase inhibitor, against triple‐negative breast cancer patient‐derived xenografts by targeting AXL/MET

International Journal of Cancer ◽

10.1002/ijc.31915 ◽

2018 ◽

Vol 144 (3) ◽

pp. 651-664 ◽

Author(s):

Yingying Shen ◽

Wei Zhang ◽

Jianghua Liu ◽

Jun He ◽

Renxian Cao ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patient ◽

Tyrosine Kinase ◽

Breast Cancer Patient ◽

Tyrosine Kinase Inhibitor ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Kinase Inhibitor ◽

Therapeutic Activity

Download Full-text

Abstract 1282: Understanding the kinomic contributions to tyrosine kinase inhibitor resistance in triple negative breast cancer

10.1158/1538-7445.am2019-1282 ◽

2019 ◽

Author(s):

Cory Lefebvre ◽

David Litchfield ◽

Alison Allan

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Kinase Inhibitor ◽

Inhibitor Resistance

Download Full-text

Abstract 3969: TP-0903, a potent AXL receptor tyrosine kinase inhibitor, enhances the activity of anti-PD-1 therapy in a metastatic preclinical syngeneic model of breast cancer

10.1158/1538-7445.sabcs18-3969 ◽

2019 ◽

Author(s):

Yuka Kumagai ◽

Jun Oishi ◽

Megumi Nakamura ◽

Jason M. Foulks ◽

Clifford J. Whatcott ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Axl Receptor Tyrosine Kinase ◽

Syngeneic Model

Download Full-text

The tyrosine kinase inhibitor dasatinib blocks tumour growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz238.032 ◽

2019 ◽

Vol 30 ◽

pp. v10

Author(s):

M. Nuncia-Cantarero ◽

C. Nieto-Jiménez ◽

M. Burgos ◽

J.C. Montero ◽

A. Ocaña ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cancer Cells ◽

Triple Negative Breast Cancer ◽

Tumour Growth ◽

Triple Negative ◽

Kinase Inhibitor

Download Full-text

S-(−)-Oleocanthal as a c-Met receptor tyrosine kinase inhibitor and its application to synergize targeted therapies and prevent breast cancer recurrence

Olives and Olive Oil in Health and Disease Prevention ◽

10.1016/b978-0-12-819528-4.00037-7 ◽

2021 ◽

pp. 681-691

Author(s):

Khalid A. El Sayed

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Targeted Therapies ◽

Kinase Inhibitor ◽

Cancer Recurrence ◽

Breast Cancer Recurrence ◽

Receptor Tyrosine Kinase Inhibitor ◽

Met Receptor Tyrosine Kinase

Download Full-text

Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer.

10.1158/0008-5472.sabcs-37 ◽

2009 ◽

Author(s):

HJ Burstein ◽

Y Sun ◽

AR Tan ◽

L Dirix ◽

JJ Vermette ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Erbb Receptor ◽

Phase 2 ◽

Receptor Tyrosine Kinase Inhibitor ◽

Her2 Breast Cancer ◽

Erbb Receptor Tyrosine Kinase

Download Full-text

Abstract 1282: Understanding the kinomic contributions to tyrosine kinase inhibitor resistance in triple negative breast cancer

10.1158/1538-7445.sabcs18-1282 ◽

2019 ◽

Author(s):

Cory Lefebvre ◽

David Litchfield ◽

Alison Allan

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Kinase Inhibitor ◽

Inhibitor Resistance

Download Full-text

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-12-0275-t ◽

2012 ◽

Vol 12 (2) ◽

pp. 131-140 ◽

Author(s):

Ezia Bello ◽

Giulia Taraboletti ◽

Gennaro Colella ◽

Massimo Zucchetti ◽

Daniele Forestieri ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Kinase Inhibitor ◽

Advanced Stage ◽

Breast Cancer Xenografts

Download Full-text

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancer

Breast Cancer Research ◽

10.1186/bcr2280 ◽

2009 ◽

Vol 11 (S1) ◽

Author(s):

H Cortés-Funes ◽

C Mendiola ◽

L Manso ◽

E Ciruelos

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Her2 Breast Cancer

Download Full-text

P3-14-09: A Phase II Preoperative Study of Dasatinib, a Multi-Targeted Tyrosine Kinase Inhibitor, in Locally Advanced “Triple-Negative” Breast Cancer Patients.

10.1158/0008-5472.sabcs11-p3-14-09 ◽

2011 ◽

Author(s):

MF Rimawi ◽

AA Rodriguez ◽

WT Yang ◽

AM Gonzalez-Angulo ◽

JR Nangia ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cancer Patients ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Kinase Inhibitor ◽

Locally Advanced ◽

Breast Cancer Patients

Download Full-text